On demand treatment and home therapy of hereditary angioedema in Germany - the Frankfurt experience
- PMID: 20667124
- PMCID: PMC2920239
- DOI: 10.1186/1710-1492-6-21
On demand treatment and home therapy of hereditary angioedema in Germany - the Frankfurt experience
Abstract
Background: Manifestation of acute edema in hereditary angioedema (HAE) is characterized by interindividual and intraindividual variability in symptom expression over time. Flexible therapy options are needed.
Methods: We describe and report on the outcomes of the highly individualized approach to HAE therapy practiced at our HAE center in Frankfurt (Germany).
Results: The HAE center at the Frankfurt University Hospital currently treats 450 adults with HAE or AAE and 107 pediatric HAE patients with highly individualized therapeutic approaches. 73.9% of the adult patients treat HAE attacks by on-demand therapy with pasteurized pd C1-INH concentrate, 9.8% use additional prophylaxis with attenuated androgens, 1% of the total patient population in Frankfurt has been treated with Icatibant up to now. In addition adult and selected pediatric patients with a high frequency of severe attacks are instructed to apply individual replacement therapy (IRT) with pasteurized pd C1-INH concentrate. Improvement on Quality of Life items was shown for these patients compared to previous long-term danazol prophylaxis. Home treatment of HAE patients was developed in the Frankfurt HAE center in line with experiences in hemophilia therapy and has so far been implemented over a period of 28 years. At present 248 (55%) of the adult patients and 26 (24%) of the pediatric patients are practicing home treatment either as on demand or IRT treatment.
Conclusions: In conclusion, the individualized home therapies provided by our HAE center, aim to limit the disruption to normal daily activities that occurs for many HAE patients. Furthermore, we seek to optimize the economic burden of the disease while offering a maximum quality of life to our patients.
Similar articles
-
C1-inhibitor concentrate for individual replacement therapy in patients with severe hereditary angioedema refractory to danazol prophylaxis.Transfusion. 2009 Sep;49(9):1987-95. doi: 10.1111/j.1537-2995.2009.02230.x. Epub 2009 May 20. Transfusion. 2009. PMID: 19497056 Clinical Trial.
-
Comparing acquired angioedema with hereditary angioedema (types I/II): findings from the Icatibant Outcome Survey.Clin Exp Immunol. 2017 Apr;188(1):148-153. doi: 10.1111/cei.12910. Epub 2017 Feb 9. Clin Exp Immunol. 2017. PMID: 27936514 Free PMC article.
-
Current options for prophylactic treatment of hereditary angioedema in the United States: patient-based considerations.Allergy Asthma Proc. 2012 May-Jun;33(3):235-40. doi: 10.2500/aap.2012.33.3573. Allergy Asthma Proc. 2012. PMID: 22584192 Review.
-
A novel prophylaxis with C1-inhibitor concentrate in hereditary angioedema during erythema marginatum.Immunol Lett. 2017 Sep;189:90-93. doi: 10.1016/j.imlet.2017.05.015. Epub 2017 May 31. Immunol Lett. 2017. PMID: 28577900
-
The importance of recognizing and managing a rare form of angioedema: hereditary angioedema due to C1-inhibitor deficiency.Postgrad Med. 2021 Aug;133(6):639-650. doi: 10.1080/00325481.2021.1905364. Epub 2021 Jul 6. Postgrad Med. 2021. PMID: 33993830 Review.
Cited by
-
Hereditary angioedema: epidemiology, management, and role of icatibant.Biologics. 2013;7:103-13. doi: 10.2147/BTT.S27566. Epub 2013 May 3. Biologics. 2013. PMID: 23662043 Free PMC article.
-
The international WAO/EAACI guideline for the management of hereditary angioedema - The 2021 revision and update.World Allergy Organ J. 2022 Apr 7;15(3):100627. doi: 10.1016/j.waojou.2022.100627. eCollection 2022 Mar. World Allergy Organ J. 2022. PMID: 35497649 Free PMC article.
-
Hereditary angioedema: beyond international consensus - circa December 2010 - The Canadian Society of Allergy and Clinical Immunology Dr. David McCourtie Lecture.Allergy Asthma Clin Immunol. 2011 Feb 10;7(1):1. doi: 10.1186/1710-1492-7-1. Allergy Asthma Clin Immunol. 2011. PMID: 21310025 Free PMC article.
-
International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency.Allergy. 2017 Feb;72(2):300-313. doi: 10.1111/all.13001. Epub 2016 Sep 8. Allergy. 2017. PMID: 27503784 Free PMC article.
-
Pharmacological Management of Hereditary Angioedema with C1-Inhibitor Deficiency in Pediatric Patients.Paediatr Drugs. 2018 Apr;20(2):135-151. doi: 10.1007/s40272-017-0273-x. Paediatr Drugs. 2018. PMID: 29214395 Review.
References
-
- Bowen T, Cicardi M, Bork K, Zuraw B, Frank M, Ritchie B, Farkas H, Varga L, Zingale LC, Binkley K, Wagner E, Adomaitis P, Brosz K, Burnham J, Warrington R, Kalicinsky C, Mace S, McCusker C, Schellenberg R, Celeste L, Hebert J, Valentine K, Poon MC, Serushago B, Neurath D, Yang W, Lacuesta G, Issekutz A, Hamed A, Kamra P, Dean J, Kanani A, Stark D, Rivard GE, Leith E, Tsai E, Waserman S, Keith PK, Page D, Marchesin S, Longhurst HJ, Kreuz W, Rusicke E, Martinez-Saguer I, Aygören-Pürsün E, Harmat G, Füst G, Li H, Bouillet L, Caballero T, Moldovan D, Späth PJ, Smith-Foltz S, Nagy I, Nielsen EW, Bucher C, Nordenfelt P, Xiang ZY. Hereditary angiodema: a current state-of-the-art review, VII: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Managment of Hereditary Angioedema. Ann Allergy Asthma Immunol. 2008;100:S30–40. doi: 10.1016/S1081-1206(10)60584-4. - DOI - PubMed
-
- Kreuz W, Martinez-Saguer I, Aygören-Pürsün E, Rusicke E, Heller C, Klingebiel T. C1-inhibitor concentrate for individual replacement therapy in patients with severe hereditary angioedema refractory to danazol prophylaxis. Transfusion. 2009;49:1987–1995. doi: 10.1111/j.1537-2995.2009.02230.x. - DOI - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources